Video: Risk Management of Adventitious Agent Contamination in Biopharmaceutical Products - - BioPharm International

ADVERTISEMENT

Video: Risk Management of Adventitious Agent Contamination in Biopharmaceutical Products


Untitled Document

During this podcast, we will discuss the causes and implications of Adventitious Agent Contamination for pharmaceutical and biopharmaceutical manufacturers. We will discuss ways in which Lancaster Laboratories is helping manufacturers minimize the risk for this contamination to avoid production delays.

Presenter:
Jeri Ann Boose, Ph.D.
Director, Biopharmaceutical Services
Lancaster Laboratories

Katherine Bergmann, Ph.D.
Manager, Viral Safety and Viral Clearance Services
Lancaster Laboratories

Online Resources:
Register for the Live Web Conference
More Information

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here